Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  American Journal of Psychiatry

• Publication date

  2017-12-15

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1176/appi.ajp.2017.17020172PMID 29241359PMCID PMC5832545
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Does Pharmacogenomic Testing Improve Clinical Outcomes for Major Depressive Disorder? A Systematic Review of Clinical Trials and Cost-Effectiveness Studies.

  2017cited by this paper
• Human amygdala engagement moderated by early life stress exposure is a biobehavioral target for predicting recovery on antidepressants

  2016cited by this paper
• Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: a 10-week open-label study

  2016cited by this paper
• Precision psychiatry: a neural circuit taxonomy for depression and anxiety.

  2016cited by this paper
• ABCB1 Genetic Effects on Antidepressant Outcomes: A Report From the iSPOT-D Trial.

  2015cited by this paper
• The international Study to Predict Optimized Treatment in Depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment.

  2015cited by this paper
• Interaction of noradrenaline and cortisol predicts negative intrusive memories in posttraumatic stress disorder.

  2014cited by this paper
• Antidepressant pharmacogenetics

  2014cited by this paper
• HPA axis and aging in depression: systematic review and meta-analysis.

  2014cited by this paper
• Guidance for the Discontinuation or Switching of Antidepressant Therapies in Adults

  2013cited by this paper
• HPA Axis Genetic Variation, Cortisol, and Psychosis in Major Depression

  2013cited by this paper
• Annotation of functional variation in personal genomes using RegulomeDB

  2012cited by this paper
• Predictors of remission in depression to individual and combined treatments (PReDICT): study protocol for a randomized controlled trial

  2012cited by this paper
• International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol

  2011cited by this paper
• A linear complexity phasing method for thousands of genomes

  2011cited by this paper
• Changes in cortisol secretion during antidepressive treatment and cognitive improvement in patients with major depression: a longitudinal study.

  2011cited by this paper
• Transcriptional control of the glucocorticoid receptor: CpG islands, epigenetics and more.

  2010cited by this paper
• Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response.

  2010cited by this paper
• A Flexible and Accurate Genotype Imputation Method for the Next Generation of Genome-Wide Association Studies

  2009cited by this paper
• Serotonin transporter genotype, morning cortisol and subsequent depression in adolescents

  2009cited by this paper
• SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap

  2008cited by this paper
• Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders.

  2007cited by this paper
• Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment.

  2007cited by this paper
• Serotonin transporter polymorphism, memory and hippocampal volume in the elderly: association and interaction with cortisol

  2007cited by this paper
• Different responses to dexamethasone and prednisolone in the same depressed patients

  2006cited by this paper
• Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans

  2004cited by this paper
• Corticotropin-Releasing Hormone Directly Activates Noradrenergic Neurons of the Locus Ceruleus Recorded In Vitro

  2004cited by this paper
• Cortisol responses to combined dexamethasone/CRH test in outpatients with a major depressive episode.

  2004cited by this paper
• The corticotropin-releasing hormone binding protein is associated with major depression in a population from Northern Sweden.

  2003cited by this paper
• The combined DEX-CRH test in treatment course and long-term outcome of major depression.

  2002cited by this paper
• Gene-based SNP genetic association study of the corticotropin-releasing hormone receptor-2 (CRHR2) in major depression.

  2002cited by this paper
• Do some antidepressants work faster than others?

  2001cited by this paper
• Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression.

  2001cited by this paper
• Urinary free cortisol excretion in elderly persons with minor and major depression.

  2001cited by this paper
• 24-Hour monitoring of cortisol and corticotropin secretion in psychotic and nonpsychotic major depression.

  2000cited by this paper
• Morning cortisol as a risk factor for subsequent major depressive disorder in adult women.

  2000cited by this paper
• Corticosterone delivery to the amygdala increases corticotropin-releasing factor mRNA in the central amygdaloid nucleus and anxiety-like behavior.

  2000cited by this paper
• Corticotropin-releasing hormone receptor subtypes and emotion.

  1999cited by this paper
• Role of the Hippocampus, the Bed Nucleus of the Stria Terminalis, and the Amygdala in the Excitatory Effect of Corticotropin-Releasing Hormone on the Acoustic Startle Reflex

  1997cited by this paper
• Corticotropin‐Releasing Factor (CRF), CRF‐Binding Protein (CRF‐BP), and CRF/CRF‐BP Complex in Alzheimer's Disease and Control Postmortem Human Brain

  1997cited by this paper
• Diurnal neuroendocrine and autonomic function in acute and remitted depressed male patients.

  1995cited by this paper
• High Plasma Concentrations of Cortisol and Thromboxane B2 in Patients With Depression

  1994cited by this paper
• Effects of electroconvulsive therapy on the CRH-ACTH-cortisol system in melancholic depression: preliminary findings.

  1994cited by this paper
• Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression.

  1993cited by this paper
• Elevated CSF CRF in suicide victims.

  1989cited by this paper
• Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients.

  1984cited by this paper
• Cortisol hypersecretion and cognitive impairment in depression.

  1984cited by this paper
• Urinary free Cortisol excretion in depression

  1976cited by this paper

• Picking Antidepressants-Patient Preferences Beat Biomarkers.

  2026cites this paper
• Distinct antidepressant therapies act on a common brain network

  2026cites this paper
• The Therapeutic Effects of Saikosaponins on Depression through the Modulation of Neuroplasticity: From Molecular Mechanisms to Potential Clinical Applications.

  2024cites this paper
• A Stress Protein–Based Suicide Prediction Score and Relationship to Reported Early-Life Adversity and Recent Life Stress

  2023cites this paper
• Precision Medicine in Antidepressants Treatment.

  2023cites this paper
• Targeting the Arginine Vasopressin V1b Receptor System and Stress Response in Depression and Other Neuropsychiatric Disorders

  2023cites this paper
• Candidate biomarkers in psychiatric disorders: state of the field

  2023cites this paper
• Transcriptome analysis of the cerebral cortex of acrylamide-exposed wild-type and IL-1β-knockout mice

  2023cites this paper
• Pharmacogenomic testing for antidepressant treatment selection: lessons learned and roadmap forward

  2023cites this paper
• Precision Medicine Approaches to Mental Healthcare.

  2022cites this paper
• Racial Differences in Antidepressant Use in Nursing Facility Residents With Moderate to Severe Cognitive Impairment.

  2022cites this paper
• Lost in translation. The quest for definitions of treatment-resistant depression with a focus on inflammation-related gene expression

  2021cites this paper
• Corticosterone-induced Hippocampal 5-HT Responses were Muted in Depressive-like State.

  2021cites this paper
• Precision Psychiatry: Biomarker-Guided Tailored Therapy for Effective Treatment and Prevention in Major Depression.

  2021cites this paper
• Early-pregnancy maternal body mass index is associated with common DNA methylation markers in cord blood and placenta: a paired-tissue epigenome-wide association study

  2021cites this paper
• Corticotropin Releasing Factor Binding Protein as a Novel Target to Restore Brain Homeostasis: Lessons Learned From Alcohol Use Disorder Research

  2021cites this paper
• Pharmacogenomics: A road ahead for precision medicine in psychiatry

  2021cites this paper
• The Long-Term Biological and Clinical Consequences of Child Abuse and Neglect

  2021cites this paper
• Transcriptional and Epigenetic Regulation of the Corticotropin-Releasing Hormone System and Genetic Associations With Neuropsychiatric Disorders

  2021cites this paper
• Pharmacogenetics of inhaled corticosteroids and exacerbation risk in adults with asthma

  2021cites this paper
• Personalized Therapy of Psychiatric Disorders

  2020cites this paper
• Pharmacogenomic testing and antidepressant response: problems and promises

  2020cites this paper
• Corticotropin releasing hormone receptor CRHR1 gene is associated with tianeptine antidepressant response in a large sample of outpatients from real-life settings

  2020cites this paper
• ERICH3: vesicular association and antidepressant treatment response

  2020cites this paper
• Pharmacogenomics and Biomarkers of Depression.

  2019cites this paper
• Genetic Advance in Depressive Disorder.

  2019cites this paper
• Depressive Disorders: Mechanisms, Measurement and Management

  2019cites this paper
• Biomarker-Guided Tailored Therapy.

  2019cites this paper
• [Perspectives of the use of pharmacogenetic tests in neurology and psychiatry].

  2019cites this paper
• Future Directions in Human Behavioral Endocrinology

  2019cites this paper
• Convergent neurobiological predictors of mood and anxiety symptoms and treatment response

  2019cites this paper
• Biomarker-Based Treatment Selection: A Precision Medicine Approach for Depression

  2019cites this paper
• Polymorphisms in genes related to the hypothalamic‐pituitary‐adrenal axis and antidepressant response – Systematic review

  2019cites this paper
• Corticotropin-Releasing Hormone Binding Protein: Stress, Psychopathology, and Antidepressant Treatment Response.

  2018cites this paper
• HPA-axis genes as potential risk variants for neurocognitive decline in trauma-exposed, HIV-positive females

  2018cites this paper
• The Corticotropin-Releasing Factor Family: Physiology of the Stress Response.

  2018cites this paper
• Clinical Implementation of Pharmacogenetic Decision Support Tools for Antidepressant Drug Prescribing.

  2018cites this paper
• Importance of the brain corticosteroid receptor balance in metaplasticity, cognitive performance and neuro-inflammation.

  2018cites this paper